Global Cannabinoid-based Products for Cancer Market
Global Cannabinoid-based Products for Cancer Market

Cannabinoid-based Products for Cancer Comprehensive Study by Type (Phytocannabinoids, Endocannabinoids, Synthetics), Application (Medical, Recreational), Components (THC-dominant, CBD-Dominant, Balanced THC, CBD), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Cannabinoid-based Products for Cancer Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 201 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
The study covers a detailed analysis segmented by key business segments i.e. by type (Phytocannabinoids, Endocannabinoids and Synthetics) , by application (Medical and Recreational) and major geographies. Research Analyst at AMA predicts that North America Players will contribute to the maximum growth of Global Cannabinoid-based Products for Cancer market throughout the predicted period.

What is Cannabinoid-based Products for Cancer?
Cancer can be treated using cannabinoid medications, which are naturally occurring recreational substances used to treat anorexia, chronic pain, and nausea and vomiting. The term "cannabinoid" refers to a class of medications that share structural similarities with tetrahydro cannabinoids. Pharma companies make it to treat a variety of conditions, including various chronic and acute migraines, sclerosis, seizures, rheumatoid arthritis, and more. Due to rising demand for cannabis medications to treat chronic pain in various indications, the Cannabinoid Drugs market is likely to rise significantly in the approaching years. Furthermore, the end-user of Cannabinoid Drugs is expected to be influenced by healthcare expenditure in the field of dermatology, which is backed by FDA approvals.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Cannabinoid-based Products for Cancer market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • GW Pharmaceuticals (United Kingdom)
  • Canopy Growth Corporation (Canada)
  • AbbVie Inc (United States)
  • Bausch Health (Canada)
  • Medical Marijuana, Inc. (United States)
  • Insys Therapeutics, Inc. (United States)
  • Stenocare (Denmark)


Market Overview:
September 2020 – AbbVie Inc. ABBV announced that it has inked a global collaboration deal with China’s I-Mab IMAB for the development and commercialization of the latter’s lemzoparlimab (also known as TJC4) to treat multiple types of cancers
the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition. The agency has, however, approved one cannabis-derived drug product: Epidiolex (cannabidiol), and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). These approved drug products are only available with a prescription from a licensed healthcare provider. Importantly, the FDA has not approved any other cannabis, cannabis-derived, or cannabidiol (CBD) products currently available on the market.

Market Trend
Several Benefits offered by these Products
Restraints
  • Various Product regulations and Marketing Regulations
  • Cannabis is Still Banned in Several Countries

Opportunities
Increase in R&D and Technological Advantages

Key highlights of the Global Cannabinoid-based Products for Cancer market Study:
• CAGR of the market during the forecast period 2020-2026
• In-depth information on growth factors that will accelerate the Cannabinoid-based Products for Cancer market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Cannabinoid-based Products for Cancer market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Cannabinoid-based Products for Cancer Players

Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cannabinoid-based Products for Cancer market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cannabinoid-based Products for Cancer market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Medical Companies, Pharmaceutical Companies, Medical Research Companies, Hospitals, Regulatory Bodies, Government Bodies and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. Where the Cannabinoid-based Products for Cancer industry is heading?
Cannabinoid-based Products for Cancer Market is heading robustly to achieve new growth cycle.

2. Is Cannabinoid-based Products for Cancer market is changing from growth to value?
The Concentration Rate of Global Cannabinoid-based Products for Cancer market is dominated by North America Players to generate healthy valuation by 2026.

3. Who are the key players profiled in the Cannabinoid-based Products for Cancer Market?
Companies that are profiled in Global Cannabinoid-based Products for Cancer Market are GW Pharmaceuticals (United Kingdom), Canopy Growth Corporation (Canada), AbbVie Inc (United States), Bausch Health (Canada), Medical Marijuana, Inc. (United States), Insys Therapeutics, Inc. (United States) and Stenocare (Denmark) etc.
Report Objectives / Segmentation Covered
By Type
  • Phytocannabinoids
  • Endocannabinoids
  • Synthetics
By Application
  • Medical
  • Recreational
By Components
  • THC-dominant
  • CBD-Dominant
  • Balanced THC
  • CBD

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Incidents of Cancer
      • 3.2.2. Increase in Legalization of Cannabis and Rise in Social Acceptance of Marijuana
    • 3.3. Market Challenges
      • 3.3.1. High Probabilities of Product Contamination
    • 3.4. Market Trends
      • 3.4.1. Several Benefits offered by these Products
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cannabinoid-based Products for Cancer, by Type, Application, Components, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cannabinoid-based Products for Cancer (Value)
      • 5.2.1. Global Cannabinoid-based Products for Cancer by: Type (Value)
        • 5.2.1.1. Phytocannabinoids
        • 5.2.1.2. Endocannabinoids
        • 5.2.1.3. Synthetics
      • 5.2.2. Global Cannabinoid-based Products for Cancer by: Application (Value)
        • 5.2.2.1. Medical
        • 5.2.2.2. Recreational
      • 5.2.3. Global Cannabinoid-based Products for Cancer by: Components (Value)
        • 5.2.3.1. THC-dominant
        • 5.2.3.2. CBD-Dominant
        • 5.2.3.3. Balanced THC
        • 5.2.3.4. CBD
      • 5.2.4. Global Cannabinoid-based Products for Cancer by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Cannabinoid-based Products for Cancer Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cannabinoid-based Products for Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GW Pharmaceuticals (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Canopy Growth Corporation (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medical Marijuana, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Insys Therapeutics, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Stenocare (Denmark)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Cannabinoid-based Products for Cancer Sale, by Type, Application, Components, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cannabinoid-based Products for Cancer (Value)
      • 7.2.1. Global Cannabinoid-based Products for Cancer by: Type (Value)
        • 7.2.1.1. Phytocannabinoids
        • 7.2.1.2. Endocannabinoids
        • 7.2.1.3. Synthetics
      • 7.2.2. Global Cannabinoid-based Products for Cancer by: Application (Value)
        • 7.2.2.1. Medical
        • 7.2.2.2. Recreational
      • 7.2.3. Global Cannabinoid-based Products for Cancer by: Components (Value)
        • 7.2.3.1. THC-dominant
        • 7.2.3.2. CBD-Dominant
        • 7.2.3.3. Balanced THC
        • 7.2.3.4. CBD
      • 7.2.4. Global Cannabinoid-based Products for Cancer by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Cannabinoid-based Products for Cancer Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cannabinoid-based Products for Cancer: by Type(USD Million)
  • Table 2. Cannabinoid-based Products for Cancer Phytocannabinoids , by Region USD Million (2015-2020)
  • Table 3. Cannabinoid-based Products for Cancer Endocannabinoids , by Region USD Million (2015-2020)
  • Table 4. Cannabinoid-based Products for Cancer Synthetics , by Region USD Million (2015-2020)
  • Table 5. Cannabinoid-based Products for Cancer: by Application(USD Million)
  • Table 6. Cannabinoid-based Products for Cancer Medical , by Region USD Million (2015-2020)
  • Table 7. Cannabinoid-based Products for Cancer Recreational , by Region USD Million (2015-2020)
  • Table 8. Cannabinoid-based Products for Cancer: by Components(USD Million)
  • Table 9. Cannabinoid-based Products for Cancer THC-dominant , by Region USD Million (2015-2020)
  • Table 10. Cannabinoid-based Products for Cancer CBD-Dominant , by Region USD Million (2015-2020)
  • Table 11. Cannabinoid-based Products for Cancer Balanced THC , by Region USD Million (2015-2020)
  • Table 12. Cannabinoid-based Products for Cancer CBD , by Region USD Million (2015-2020)
  • Table 13. Cannabinoid-based Products for Cancer: by Distribution Channel(USD Million)
  • Table 14. Cannabinoid-based Products for Cancer Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 15. Cannabinoid-based Products for Cancer Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 16. Cannabinoid-based Products for Cancer Online Pharmacies , by Region USD Million (2015-2020)
  • Table 17. South America Cannabinoid-based Products for Cancer, by Country USD Million (2015-2020)
  • Table 18. South America Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 19. South America Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 20. South America Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 21. South America Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 22. Brazil Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 23. Brazil Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 24. Brazil Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 25. Brazil Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 26. Argentina Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 27. Argentina Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 28. Argentina Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 29. Argentina Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 30. Rest of South America Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 32. Rest of South America Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 33. Rest of South America Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 34. Asia Pacific Cannabinoid-based Products for Cancer, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 37. Asia Pacific Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 38. Asia Pacific Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 39. China Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 40. China Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 41. China Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 42. China Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 43. Japan Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 44. Japan Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 45. Japan Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 46. Japan Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 47. India Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 48. India Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 49. India Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 50. India Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 51. South Korea Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 52. South Korea Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 53. South Korea Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 54. South Korea Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 55. Taiwan Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 56. Taiwan Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 57. Taiwan Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 58. Taiwan Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 59. Australia Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 60. Australia Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 61. Australia Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 62. Australia Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 67. Europe Cannabinoid-based Products for Cancer, by Country USD Million (2015-2020)
  • Table 68. Europe Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 69. Europe Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 70. Europe Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 71. Europe Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 72. Germany Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 73. Germany Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 74. Germany Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 75. Germany Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 76. France Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 77. France Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 78. France Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 79. France Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 80. Italy Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 81. Italy Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 82. Italy Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 83. Italy Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 84. United Kingdom Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 85. United Kingdom Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 86. United Kingdom Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 87. United Kingdom Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 88. Netherlands Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 89. Netherlands Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 90. Netherlands Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 91. Netherlands Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 92. Rest of Europe Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 93. Rest of Europe Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 94. Rest of Europe Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 95. Rest of Europe Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 96. MEA Cannabinoid-based Products for Cancer, by Country USD Million (2015-2020)
  • Table 97. MEA Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 98. MEA Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 99. MEA Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 100. MEA Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 101. Middle East Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 102. Middle East Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 103. Middle East Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 104. Middle East Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 105. Africa Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 106. Africa Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 107. Africa Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 108. Africa Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 109. North America Cannabinoid-based Products for Cancer, by Country USD Million (2015-2020)
  • Table 110. North America Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 111. North America Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 112. North America Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 113. North America Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 114. United States Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 115. United States Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 116. United States Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 117. United States Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 118. Canada Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 119. Canada Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 120. Canada Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 121. Canada Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 122. Mexico Cannabinoid-based Products for Cancer, by Type USD Million (2015-2020)
  • Table 123. Mexico Cannabinoid-based Products for Cancer, by Application USD Million (2015-2020)
  • Table 124. Mexico Cannabinoid-based Products for Cancer, by Components USD Million (2015-2020)
  • Table 125. Mexico Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2015-2020)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Cannabinoid-based Products for Cancer: by Type(USD Million)
  • Table 134. Cannabinoid-based Products for Cancer Phytocannabinoids , by Region USD Million (2021-2026)
  • Table 135. Cannabinoid-based Products for Cancer Endocannabinoids , by Region USD Million (2021-2026)
  • Table 136. Cannabinoid-based Products for Cancer Synthetics , by Region USD Million (2021-2026)
  • Table 137. Cannabinoid-based Products for Cancer: by Application(USD Million)
  • Table 138. Cannabinoid-based Products for Cancer Medical , by Region USD Million (2021-2026)
  • Table 139. Cannabinoid-based Products for Cancer Recreational , by Region USD Million (2021-2026)
  • Table 140. Cannabinoid-based Products for Cancer: by Components(USD Million)
  • Table 141. Cannabinoid-based Products for Cancer THC-dominant , by Region USD Million (2021-2026)
  • Table 142. Cannabinoid-based Products for Cancer CBD-Dominant , by Region USD Million (2021-2026)
  • Table 143. Cannabinoid-based Products for Cancer Balanced THC , by Region USD Million (2021-2026)
  • Table 144. Cannabinoid-based Products for Cancer CBD , by Region USD Million (2021-2026)
  • Table 145. Cannabinoid-based Products for Cancer: by Distribution Channel(USD Million)
  • Table 146. Cannabinoid-based Products for Cancer Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 147. Cannabinoid-based Products for Cancer Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 148. Cannabinoid-based Products for Cancer Online Pharmacies , by Region USD Million (2021-2026)
  • Table 149. South America Cannabinoid-based Products for Cancer, by Country USD Million (2021-2026)
  • Table 150. South America Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 151. South America Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 152. South America Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 153. South America Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 154. Brazil Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 155. Brazil Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 156. Brazil Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 157. Brazil Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 158. Argentina Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 159. Argentina Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 160. Argentina Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 161. Argentina Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 162. Rest of South America Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 163. Rest of South America Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 164. Rest of South America Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 165. Rest of South America Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 166. Asia Pacific Cannabinoid-based Products for Cancer, by Country USD Million (2021-2026)
  • Table 167. Asia Pacific Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 168. Asia Pacific Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 169. Asia Pacific Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 170. Asia Pacific Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 171. China Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 172. China Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 173. China Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 174. China Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 175. Japan Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 176. Japan Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 177. Japan Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 178. Japan Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 179. India Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 180. India Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 181. India Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 182. India Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 183. South Korea Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 184. South Korea Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 185. South Korea Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 186. South Korea Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 187. Taiwan Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 188. Taiwan Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 189. Taiwan Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 190. Taiwan Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 191. Australia Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 192. Australia Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 193. Australia Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 194. Australia Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 195. Rest of Asia-Pacific Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 199. Europe Cannabinoid-based Products for Cancer, by Country USD Million (2021-2026)
  • Table 200. Europe Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 201. Europe Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 202. Europe Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 203. Europe Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 204. Germany Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 205. Germany Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 206. Germany Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 207. Germany Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 208. France Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 209. France Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 210. France Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 211. France Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 212. Italy Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 213. Italy Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 214. Italy Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 215. Italy Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 216. United Kingdom Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 217. United Kingdom Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 218. United Kingdom Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 219. United Kingdom Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 220. Netherlands Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 221. Netherlands Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 222. Netherlands Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 223. Netherlands Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 224. Rest of Europe Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 225. Rest of Europe Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 226. Rest of Europe Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 227. Rest of Europe Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 228. MEA Cannabinoid-based Products for Cancer, by Country USD Million (2021-2026)
  • Table 229. MEA Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 230. MEA Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 231. MEA Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 232. MEA Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 233. Middle East Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 234. Middle East Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 235. Middle East Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 236. Middle East Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 237. Africa Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 238. Africa Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 239. Africa Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 240. Africa Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 241. North America Cannabinoid-based Products for Cancer, by Country USD Million (2021-2026)
  • Table 242. North America Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 243. North America Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 244. North America Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 245. North America Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 246. United States Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 247. United States Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 248. United States Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 249. United States Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 250. Canada Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 251. Canada Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 252. Canada Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 253. Canada Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 254. Mexico Cannabinoid-based Products for Cancer, by Type USD Million (2021-2026)
  • Table 255. Mexico Cannabinoid-based Products for Cancer, by Application USD Million (2021-2026)
  • Table 256. Mexico Cannabinoid-based Products for Cancer, by Components USD Million (2021-2026)
  • Table 257. Mexico Cannabinoid-based Products for Cancer, by Distribution Channel USD Million (2021-2026)
  • Table 258. Research Programs/Design for This Report
  • Table 259. Key Data Information from Secondary Sources
  • Table 260. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cannabinoid-based Products for Cancer: by Type USD Million (2015-2020)
  • Figure 5. Global Cannabinoid-based Products for Cancer: by Application USD Million (2015-2020)
  • Figure 6. Global Cannabinoid-based Products for Cancer: by Components USD Million (2015-2020)
  • Figure 7. Global Cannabinoid-based Products for Cancer: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Cannabinoid-based Products for Cancer Share (%), by Country
  • Figure 9. Asia Pacific Cannabinoid-based Products for Cancer Share (%), by Country
  • Figure 10. Europe Cannabinoid-based Products for Cancer Share (%), by Country
  • Figure 11. MEA Cannabinoid-based Products for Cancer Share (%), by Country
  • Figure 12. North America Cannabinoid-based Products for Cancer Share (%), by Country
  • Figure 13. Global Cannabinoid-based Products for Cancer share by Players 2020 (%)
  • Figure 14. Global Cannabinoid-based Products for Cancer share by Players (Top 3) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GW Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GW Pharmaceuticals (United Kingdom) Revenue: by Geography 2020
  • Figure 18. Canopy Growth Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 19. Canopy Growth Corporation (Canada) Revenue: by Geography 2020
  • Figure 20. AbbVie Inc (United States) Revenue, Net Income and Gross profit
  • Figure 21. AbbVie Inc (United States) Revenue: by Geography 2020
  • Figure 22. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 23. Bausch Health (Canada) Revenue: by Geography 2020
  • Figure 24. Medical Marijuana, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Medical Marijuana, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Insys Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Insys Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Stenocare (Denmark) Revenue, Net Income and Gross profit
  • Figure 29. Stenocare (Denmark) Revenue: by Geography 2020
  • Figure 30. Global Cannabinoid-based Products for Cancer: by Type USD Million (2021-2026)
  • Figure 31. Global Cannabinoid-based Products for Cancer: by Application USD Million (2021-2026)
  • Figure 32. Global Cannabinoid-based Products for Cancer: by Components USD Million (2021-2026)
  • Figure 33. Global Cannabinoid-based Products for Cancer: by Distribution Channel USD Million (2021-2026)
  • Figure 34. South America Cannabinoid-based Products for Cancer Share (%), by Country
  • Figure 35. Asia Pacific Cannabinoid-based Products for Cancer Share (%), by Country
  • Figure 36. Europe Cannabinoid-based Products for Cancer Share (%), by Country
  • Figure 37. MEA Cannabinoid-based Products for Cancer Share (%), by Country
  • Figure 38. North America Cannabinoid-based Products for Cancer Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GW Pharmaceuticals (United Kingdom)
  • Canopy Growth Corporation (Canada)
  • AbbVie Inc (United States)
  • Bausch Health (Canada)
  • Medical Marijuana, Inc. (United States)
  • Insys Therapeutics, Inc. (United States)
  • Stenocare (Denmark)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation